Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China

Zheng, Xin; Wang, Hua; Sū, Zhèngyuán; Li, Wei; Yang, Dongliang; Deng, Fei; Chen, Jianjun

doi:10.1016/j.jinf.2020.05.041

Cited by 56 publications

(60 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also detected multiple co-detection of SARS-CoV-2 with other respiratory viruses, such as influenza A and B and human metapneumovirus, which have also been reported elsewhere 40,41 . Although, co-infections with other respiratory viruses have been reported in other countries 40,42,43 , no difference in clinical disease severity between cases with and without viral co-infection has been observed thus far 44 . The co-circulation of other respiratory pathogens highlights the need to scale up laboratory and molecular screening of SARS-CoV-2 and other respiratory viruses in public laboratories across Brazil 15 .…”

Section: Discussionmentioning

confidence: 89%

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

Buss²,

et al. 2020

View full text Add to dashboard Cite

OVID-19 is a severe acute respiratory infection (SARI) that emerged in early December 2019 in Wuhan, China 1. The outbreak was declared a public health emergency of international concern by the World Health Organization on 30 January 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded positive-sense RNA virus that belongs to the Betacoronavirus genus and Coronaviridae family 2. SARS-CoV-2 is closely related genetically to bat-derived SARS-like coronaviruses 3. Human-to-human transmission occurs primarily via respiratory droplets and direct contact, similar to human influenza viruses, SARS-CoV and Middle East respiratory syndrome coronavirus 4. The most commonly reported clinical symptoms are fever, dry cough, fatigue, dyspnoea, anosmia, ageusia, or some combination of these 1,4,5. As of 16 June 2020, more than 7.9 million cases have been confirmed worldwide, resulting in 434,796 deaths 6. Brazil declared COVID-19 a national public health emergency on 3 February 2020 7. After the development of a national emergency plan and the early establishment of molecular diagnostic facilities across Brazil's network of public health laboratories, the country reported its first confirmed COVID-19 case on 25 February 2020, in a traveller returning to São Paulo from northern Italy 8. São Paulo is the largest city in South America and no other Brazilian city receives a greater proportion of international flights 9. Currently, Brazil has one of the fastest-growing COVID-19 epidemics in the world, now accounting for 1,864,681 cases and 72,100 deaths, comprising over 55% of the total number of reported cases in Latin America and the Caribbean (as of 14 July 2020) 6. About 21% of Latin American and Caribbean populations are estimated to be at risk of severe COVID-19 illness 10. The region has been experiencing large outbreaks, with growing epidemics in Brazil,

show abstract

Section: Discussionmentioning

confidence: 89%

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

Buss²,

et al. 2020

View full text Add to dashboard Cite

show abstract

“…have report the symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection -named coronavirus disease 2019 (COVID-19)- appear very similar to influenza. 1 We would like to share our findings for SARS-CoV-2 and influenza virus infections as virus co-circulation is likely to occur in future. 2 It is important to facilitate differential diagnosis.…”

mentioning

confidence: 72%

Medical features of COVID-19 and influenza infection: A comparative study in Paris, France

Faury

Courboulès

Payen

et al. 2021

Journal of Infection

View full text Add to dashboard Cite

Highlights COVID-19 and influenza patients share overweight as a risk factor for severe infection. Higher death rate was reported in COVID-19 group than in influenza group. COVID-19 patients developed preferentially secondary respiratory failure. Older age and diabetes were confirmed as major contributing death risk factors in COVID-19.

show abstract

“… 9 In contrast, another study only reported mild symptoms in limited coinfection outpatients. 10 A retrospective study found that the coinfection rate of SARS‐CoV‐2 and influenza virus was as high as 57.3% (among which 49.8% was coinfected with IAV) in a single‐centered study of 307 COVID-19 patients during the outbreak period in Wuhan. 11 Thus, the high coinfection rate and the unpredictable clinical outcomes pose great concerns when facing the threat of both viruses.…”

Section: Introductionmentioning

confidence: 99%

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity

et al. 2021

View full text Add to dashboard Cite

The upcoming flu season in the Northern Hemisphere merging with the current COVID-19 pandemic raises a potentially severe threat to public health. Through experimental coinfection with influenza A virus (IAV) and either pseudotyped or live SARS-CoV-2 virus, we found that IAV preinfection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types. Remarkably, in vivo, increased SARS-CoV-2 viral load and more severe lung damage were observed in mice coinfected with IAV. Moreover, such enhancement of SARS-CoV-2 infectivity was not observed with several other respiratory viruses, likely due to a unique feature of IAV to elevate ACE2 expression. This study illustrates that IAV has a unique ability to aggravate SARS-CoV-2 infection, and thus, prevention of IAV infection is of great significance during the COVID-19 pandemic.

show abstract

Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China

Abstract: Co-infection of SARS-CoV-2 and Influenza virus in EarlyStage of the COVID-19 Epidemic in Wuhan, China

Cited by 56 publications

References 7 publications

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

Medical features of COVID-19 and influenza infection: A comparative study in Paris, France

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity

Contact Info

Product

Resources

About